Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.

McGarry, Lisa J; Bhaiwala, Zahra; Lopez, Andrea; Chandler, Conor; Pelligra, Christopher G; Rubin, Jaime L; Liou, Theodore G

McGarry, Lisa J; Bhaiwala, Zahra; Lopez, Andrea; Chandler, Conor; Pelligra, Christopher G; Rubin, Jaime L; Liou, Theodore G.

Affiliation

McGarry LJ; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
Bhaiwala Z; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
Lopez A; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
Chandler C; Evidera, Waltham, MA, United States of America.
Pelligra CG; Evidera, Bogotá, Colombia.
Rubin JL; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
Liou TG; Adult CF Center, University of Utah, Salt Lake City, UT, United States of America.

PLoS One ; 18(4): e0283479, 2023.

Article in En | MEDLINE | ID: mdl-37043485

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Document type: Article Affiliation country: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google